Forest's Lexapro approved in US for depression in adolescents
This article was originally published in Scrip
Executive Summary
The US FDA has approved Forest Laboratories' SSRI antidepressant Lexapro (escitalopram) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents aged 12 to 17 years old.